Browse News
Filter News
Found 31 articles
-
Weston Miller, M.D., senior medical director of clinical development at Astellas Gene Therapies, called the positive interim and tolerability data an important waypoint.
-
GRO Biosciences Appoints Rakhshita Dhar to its Board of Directors
1/18/2022
GRO Biosciences Inc. today announced the appointment of Rakhshita Dhar to its Board of Directors.
-
BioSpace is proud to present its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.
-
BioSpace Announces Top New Biopharma Companies to Watch in 2022
1/5/2022
BioSpace, Inc., the leading life sciences news and careers site, has announced their selections for the industry’s most exciting up-and-coming companies in 2022.
-
From the continuing fight against COVID-19 to new companies emerging in exciting therapeutic areas to the people who mattered most, here’s a look at just some of the biggest successes, most dramatic flops – and a few that fall somewhere in between.
-
With this new collaboration, Astellas will take advantage of Dynos' next-gen AAV vectors to deliver its gene therapy.
-
Astellas and Dyno Therapeutics Announce Research Collaboration to Develop Next-Generation AAV Gene Therapy Vectors for Skeletal and Cardiac Muscle
12/1/2021
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Dyno Therapeutics, Inc. (President and CEO: Eric Kelsic, Ph.D., "Dyno") today announced an option and license agreement was signed on November 23 to develop next-generation adeno-associated virus (AAV) vectors for gene therapy directed to skeletal and cardiac muscle using Dyno's CapsidMap™ platform.
-
With the Thanksgiving holiday upon us, BioSpace felt it was important to give thanks for some of the positive things that have happened this year. And there are many!
-
The United States has seen companies launching left and right. Check out the top 10 biopharma Series A rounds in the U.S. so far this year.
-
Roche will apply RNAfix and Shape’s AAVid technology platform to develop next-generation tissue-specific adeno-associated viruses for new gene therapies aimed at these indications.
-
Money on the Move: May 5 - 11
5/12/2021
Catch up on the investment news quickly with BioSpace's brief overview of the biotech companies hitting the Nasdaq and raking in fresh cash the past week. -
Dyno Therapeutics Presents State-of-the-Art Applications of Machine Learning to Design Improved AAV Capsids for a Broad Range of Gene Therapies at American Society of Gene and Cell Therapy Conference
5/11/2021
Dyno Therapeutics , a biotechnology company applying artificial intelligence (AI) to gene therapy, will describe ongoing enhancements to its machine learning platform in three oral presentations at the 24th annual meeting of the American Society of Gene and Cell Therapapies
-
Since emerging from stealth mode in 2020 Dyno Therapeutics has been busy advancing its gene therapy platform. This morning, the company bolsters its research with $100 million raised in a Series A financing round.
-
Dyno Therapeutics Closes $100 Million Series A Financing Led by Andreessen Horowitz to Accelerate AI‑powered Gene Therapy Platform
5/6/2021
Dyno Therapeutics, Inc. , a biotechnology company applying artificial intelligence (AI) to gene therapy, today announced a $100 million Series A financing led by Andreessen Horowitz, with participation from a select syndicate of new investors
-
Dyno Therapeutics Announces Presentations at 2021 American Society of Gene and Cell Therapy Annual Meeting
4/27/2021
Dyno Therapeutics , a biotech company applying artificial intelligence (AI) to gene therapy, today announced that it will deliver three oral presentations and an Industry Symposium at the 24 th annual meeting of the American Society of Gene and Cell Therapy (ASGCT) being held as a virtual meeting on May 11–14, 2021.
-
Dyno Therapeutics Names Dr. Debora Marks and Dr. Nicole Paulk to Scientific Advisory Board
4/26/2021
Dyno Therapeutics, a biotech company applying artificial intelligence (AI) to gene therapy, today announced the expansion of the company’s Scientific Advisory Board (SAB) with the addition of Debora Marks, Ph.D., of Harvard Medical School and the Broad Institute, and Nicole Paulk, Ph.D., of the University of California San Francisco
-
Dyno Therapeutics Announces Publication in Nature Biotechnology Demonstrating Use of Artificial Intelligence to Generate Unprecedented Diversity of AAV Capsids and Broaden Reach of Gene Therapies
2/11/2021
Dyno Therapeutics Announces Publication in Nature Biotechnology Demonstrating Use of Artificial Intelligence to Generate Unprecedented Diversity of AAV Capsids and Broaden Reach of Gene Therapies
-
In this multi-target partnership, Genentech will leverage Genesis’ Dynamic PotentialNet AI platform and other novel neural network algorithms.
-
Dyno will be responsible for the design of the novel AAV capsids that are expected to have improved functional properties for gene therapy. Roche and its subsidiary Spark Therapeutics will take the capsids and conduct preclinical studies with hopes of taking them into the clinic, and eventually t...
-
Dyno Therapeutics Enters Collaboration and License Agreement With Roche to Develop Next-Generation AAV Gene Therapy Vectors for CNS Diseases and Liver-Directed Therapies
10/14/2020
Collaboration combines Dyno’s AI-powered AAV vector capabilities with Roche and Spark Therapeutics’ leading-edge gene therapy capabilities